New combo therapy targets hard-to-treat breast tumors

NCT ID NCT06827613

Recruiting now Disease control Sponsor: Marengo Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination (invikafusp alfa plus sacituzumab govitecan) in people with advanced breast cancers that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and can shrink or control tumors. About 50 adults with triple-negative or hormone-receptor-positive/HER2-negative breast cancer will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+, HER2-, ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+, HER2-, ADVANCED BREAST CANCER TRIPLE NEGATIVE LOCALLY ADVANCED NON-RESECTABLE BREAST CANCER

Contacts and locations

Locations

BC Cancer
RECRUITING

Vancouver, British Columbia, V5Z 1K1, Canada
Massachusetts General Hospital Cancer Center
RECRUITING

Boston, Massachusetts, 02114, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43212, United States
Princess Margaret Cancer Centre
RECRUITING

Toronto, Ontario, M5G 2C4, Canada
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
UCLA Health
RECRUITING

Los Angeles, California, 90095, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
UT Health San Antonio MD Anderson Cancer Center
RECRUITING

San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.